drugset / Trial / NCT07362264

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

NCT07362264

Phase 1 Active not recruiting 50 enrolled Nanjing Sanhome Pharmaceutical, Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors

Timeline

Start
2025-07-01
Primary completion
2026-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SH006 Unknown 15 mg/kg
Subject SH006 Unknown 30 mg/kg

Indications